Dual Nucleoside Therapy for HIV Infection: Analysis of Results and Factors Influencing Viral Response and Long Term Efficacy | Zendy

Giustino Parruti | Zendy; Pierluigi Tarquini | Zendy; Katia Falasca | Zendy; Enzo Ballone | Zendy; Guglielmo D’Amico | Zendy; Adriana Agosti | Zendy; G. Placido | Zendy; Rita Graziani | Zendy; Dante Di Giammartino | Zendy; Margherita D’Alessandro | Zendy; Jacopo Vecchiet | Zendy; Marta Di Nicola | Zendy; F Schioppa | Zendy; L. Alterio | Zendy; Augusta Consorte | Zendy; Andrew Pieri | Zendy; G. Marani Toro | Zendy

Open Access

Dual Nucleoside Therapy for HIV Infection: Analysis of Results and Factors Influencing Viral Response and Long Term Efficacy

Author(s) -

Giustino Parruti,

Pierluigi Tarquini,

Katia Falasca,

Enzo Ballone,

Guglielmo D’Amico,

Adriana Agosti,

G. Placido,

Rita Graziani,

Dante Di Giammartino,

Margherita D’Alessandro,

Jacopo Vecchiet,

Marta Di Nicola,

F Schioppa,

L. Alterio,

Augusta Consorte,

Andrew Pieri,

G. Marani Toro

Publication year - 2003

Publication title -

international journal of immunopathology and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.724

H-Index - 53

eISSN - 2058-7384

pISSN - 0394-6320

DOI - 10.1177/039463200301600112

Subject(s) - viral load , medicine , human immunodeficiency virus (hiv) , immunology , virology , antiretroviral therapy , term (time) , physics , quantum mechanics

We performed a retrospective analysis of our experience with dual nucleoside regimens to look for predictors of long term benefit. We evaluated a cohort of 68 HIV-infected patients treated at 3 Italian hospital-based facilities. The results were analysed using univariate and multivariate statistical analyses. Fourty-three males and 25 females were treated for 22 ± 14 months. Sixty three patients (92.6%) suffered no or low-grade side-effects. Thirty-four patients (50 %) reached a viral load 150/μl pre-treatment viremia 1,500/μl, and no previous exposure to NRTI. Total lymphocyte counts and CD4+ T-cells showed a significant correlation. Dual NRTI regimens may be still considered for patients unable to tolerate HAART regimens and presenting with favourable predictors of response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research